Retrospective Cohort Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Jul 14, 2024; 30(26): 3210-3220
Published online Jul 14, 2024. doi: 10.3748/wjg.v30.i26.3210
Table 1 Basic demographics of the study population
Features
n of 605
%
Age, mean ± SD (58.2 ± 19), median = 60
< 60 years29448.6
≥ 60 years31151.4
Sex
Female29749.2
Male30750.8
Duration of symptoms
< 30 days 33062.6
30-59 days7513.2
60-89 days117.3
≥ 90 days149.3
Control without alarm features9215.2
Patients with alarm features51384.8
Alarm features
Upper GI bleeding14423.8
Unexplained weight loss13722.6
Persistent vomiting12420.5
Iron deficiency anemia508.3
Dysphagia376.1
Odynophagia50.8
Epigastric mass or lymphadenopathy10.2
Endoscopic finding
Patients without endoscopic finding43171.2
Patients with any endoscopic finding174 28.8
Peptic ulcer disease92 15.2
Erosive esophagitis class B or higher345.6
Malignancy426.9
Stricture10.2
Finding requiring specific therapy152.5
Medications
PPIs17329
Statins19132.3
Aspirin11118.8
Anticoagulant396.6
Anti-aggregate305.1
NSAIDs233.9
Table 2 Patients’ clinical and demographics characteristics at presentation in both groups with and without significant endoscopic findings, n (%)
Patients’ clinical characteristics
Total, n = 605
SEFs, n = 174
No SEFs, n = 431
P value
Sex 0.081
Female297 (49.2)94 (54)203 (47.2)
Male 307 (50.8)80 (46)227 (52.8)
Duration of symptoms0.012
< 30 days330 (62.2)106 (70.2)224 (59.6)
30-59 days75 (14.2)20 (13.2)55 (14.6)
60-89 days39 (7.4)11 (7.3)28 (7.4)
≥ 90 days83 (15.7)14 (9.3)69 (18.4)
Pulse0.0012
Bradycardia51 (8.5)10 (5.8)41 (9.5)
Normal pulse524 (86.9)146 (84.4)378 (87.9)
Tachycardia28 (4.6)17 (9.8)11 (2.6)
Blood pressure0.082
Hypotension61 (10.1)24 (13.9)37 (8.6)
Normal BP417 (69.3)116 (67.1)301 (70.2)
Hypertension124 (20.6)33 (19.1)91 (21.2)
Table 3 Patients’ blood test, n (%)
CBC
Total (%), n = 605
SEFs, n = 174
No SEFs, n = 431
P value
Normal CBC234 (38.7)39 (22.4)195 (45.2)< 0.0011
Abnormal CBC371 (61.3)135 (77.6)236 (54.8)
Normocytic anemia194 (32.1)83 (47.7)111 (25.8)< 0.0011
Microcytic anemia87 (14.4)28 (16.1)59 (13.7)0.521
Macrocytic anemia3 (0.5)1 (0.6)2 (0.5)1.03
Leukocytosis134 (22.1)52 (29.9)82 (19)0.0051
Leukopenia8 (1.3)2 (1.1)6 (1.4)1.03
Thrombocytosis18 (3.0)7 (4.0)11 (2.6)0.4271
Thrombocytopenia14 (2.3)6 (3.4)8 (1.9)0.243
CRP
CRP normal, < 5289 (47.9)83 (47.7)206 (48.0)1.001
CRP abnormal314 (52.1)91 (52.3)223 (52.0)
Albumin
Hypoalbuminemia102 (17.2)47 (28.0)55(12.9)< 0.0012
Normal albumin489 (82.3)118 (70.2)371 (87.1)
Hyperalbuminemia3 (0.5)3 (1.8)0 (0)
Liver function test
Normal554 (91.7)157 (90.2)397 (92.3)0.4161
Hepatocellular enzymes elevated39 (6.5)13 (7.5)26 (6.0)0.581
Cholestatic enzymes elevated22 (3.6)9 (5.2)13 (3.0)0.2311
Table 4 Correlation between regular medication use during dyspeptic symptom period, n (%)
Drug
Total (%), n = 605
SEFs, n = 174
No SEFs, n = 431
P value
PPI173 (29)48 (28.2)125 (29.6)0.771
NSAIDs23 (3.9)9 (5.3)14 (3.3)0.351
Aspirin111 (18.8)27 (15.9)84 (19.9)0.291
Statin191 (32.3)54 (31.8)137 (32.4)0.921
Anticoagulant39 (6.6)10 (5.9)29(6.9)0.721
Anti-aggregate30 (5.1)13 (7.6)17 (4)0.051
Table 5 Association of alarm features with significant endoscopic findings, n (%)
Alarm features
Total (%), n = 605
SEFs, n = 174
No SEFs, n = 431
P value
Unexplained weight loss137 (22.6)35 (20.1)102 (23.7)0.3911
Dysphagia37 (6.1)13 (7.5)24 (5.6)0.4531
Persistent vomiting124 (20.5)40 (23.0)84 (19.5)0.3731
Odynophagia5 (0.8) 2 (1.1)3 (0.7)0.6293
Upper GI bleeding145 (24)67 (38.5)78 (18.1)< 0.0011
IDA50 (8.3)12 (6.9)38 (8.8)0.5161
Epigastric mass or lymphadenopathy1 (0.2)01 (0.2)1.0003
Table 6 Correlation between radiologic findings during hospitalization and endoscopic findings, n (%)
Imaging modality
Total (%), n = 605
SEFs, n = 174
No SEFs, n = 431
OR
95%CI
P value
Imaging modality not performed188 (31.2)64 (37)124 (28.8)1.450.99-2.10.051
Imaging modality performed415 (68.8)109 (63)306 (71.2)
CT345 (57)n = 100n = 245
Normal abdominal CT214(62)31 (31)183 (74.7)6.573.94-11< 0.001
CT shows suspected PUD5 (0.8)2 (2.0)3 (1.2)1.650.27-1000.59
CT shows suspected SOL35 (10.1)26 (26.0)9 (3.7)9.214.13-20.54< 0.001
CT shows bowel wall thickening60 (17.4)25 (25.0)35 (14.3)21.12-3.560.02
CT shows stricture5 (0.8)2 (2.0)3 (1.2)1.650.27-100.59
CT shows metastatic disease12 (2.0)9 (9.0)3 (1.2)82.11-30.130.002
CT shows distended stomach9 (1.5)5 (5.6)4 (1.6)3.170.83-12.10.09
CT shows lymphadenopathy8 (1.3)3(3.0) 5 (2.0)1.480.35-6.330.59
US113 (18.7)n = 19n = 94
Normal abdominal US110 (97.3)19 (100)91 (96.8)01
US shows cholecystitis3 (2.7)0 (0.0)3 (3.2)
Table 7 Five models presenting the correlation between alarm features and other variables found significant in our univariate analysis and significant endoscopic findings
Model
Variables
P value
OR
95%CI for OR
1Dependent variable: Significant endoscopic finding
Persistent vomiting0.091.590.932.73
Odynophagia0.0812.650.72222.11
UGIB< 0.0013.482.075.86
Normocytic anemia0.0032.061.283.29
Leukocytosis0.021.831.113.04
Low albumin0.051.781.013.15
Duration of symptoms0.040.990.991.00
Abnormal CT2< 0.0017.834.2114.54
2Dependent variable: Significant endoscopic finding (duration of symptoms not included)
Persistent vomiting0.031.751.052.91
Odynophagia0.077.810.8572.07
UGIB< 0.0013.221.975.27
Normocytic anemia< 0.0012.361.513.69
Leukocytosis0.011.831.132.98
Hypoalbuminemia0.041.771.043.01
Abnormal CT2< 0.0018.644.8215.49
Tachycardia0.013.111.267.69
3Dependent variable: Peptic ulcer disease
Unexplained weight loss0.0090.310.130.75
Persistent vomiting0.041.921.053.75
UGIB< 0.0013.812.226.52
Normocytic anemia< 0.0013.121.775.48
Leukocytosis0.031.921.063.48
Abnormal CT20.042.291.035.10
tachycardia0.032.851.147.17
4Dependent variable: Erosive esophagitis class B or higher
Odynophagia0.00421.032.69164.31
Anti-aggregate medications0.013.941.3711.33
Leukocytosis0.0032.991.456.17
5Dependent variable: Malignancy as an endoscopic finding
Unexplained weight loss0.072.050.954.41
Abnormal CT2< 0.00139.6811.81133.33